A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Clinical trial NCT00533702 · COMPLETED

Trial details

NCT number: NCT00533702
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Malignant Melanoma

Start date: 2007-11-01
Primary completion: 2011-05-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.